SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using its proprietary electroporation-based DNA delivery platform, announced today that new interim data from a phase I clinical trial of a DNA-based immunotherapy against melanoma using Inovio’s electroporation delivery technology will be presented at the DNA Vaccines Forum 2008 being held March 10-11, 2008, at The Millennium Gloucester Hotel in London, UK. Dr. Richard Heller of the University of South Florida and Moffitt Cancer Center will make the presentation, “Investigating Positive Outcomes in the Clinic Supporting Successful Implementation of DNA Vaccine Delivery through Electroporation,” on Tuesday, March 11th, at 11:50 a.m. Inovio’s electroporation delivery technology is intended to enhance the potency of DNA-based immunotherapies including DNA vaccines.
